Roche Diagnostics Corporation and Oxford University: Cooperation to Evaluate 454 Sequencing and NimbleGen Systems, Inc. High-Density Arrays for Genetic Disease Analysis

BURGESS HILL, England--(BUSINESS WIRE)--Roche Diagnostics Ltd. today announced that they will support the Oxford Biomedical Research Centre (OxBRC) - a partnership between the Oxford Radcliffe Hospitals NHS Trust and University of Oxford - in the development of solutions enabling improved genetic and cytogenetic testing. Using the next-generation sequencing technology of 454 Sequencing and high-density arrays of Roche NimbleGen, the Oxford BRC will work on improved solutions for the analysis of genetic diseases.

Back to news